Innovis Asset Management’s 89bio ETNB Stock Holding History

Innovis Asset Management’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,437	Closed	-$198K	–	158
2023 Q2	$198K	Buy	+10,437	New	+$183K	0.07%	151

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Innovis Asset Management's ETNB Position: Q3 2023 in Review

Innovis Asset Management sold out of 89bio (ETNB) in Q3 2023, closing a stake of 10,437 shares — an estimated $198K sold.

Innovis Asset Management first reported a position in ETNB in Q2 2023 and held it in 1 quarter. The position peaked at $198K in Q2 2023. 160 funds tracked by Wall St. Rank hold ETNB as of Q3 2023.

Innovis Asset Management reported no remaining 89bio position as of Q3 2023 after selling out during the quarter.
Innovis Asset Management sold 10,437 89bio shares in Q3 2023, an estimated $198K.
Innovis Asset Management first reported a position in 89bio in Q2 2023 and held it in 1 quarter.
Innovis Asset Management's 89bio position peaked at $198K in Q2 2023.
160 funds tracked by Wall St. Rank held 89bio as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.